An FDA advisory committee on Wednesday unanimously voted against recommending approval of the PARP inhibitor talazoparib (Talzenna) plus enzalutamide (Xtandi) for all patients with metastatic ...

In advanced or metastatic prostate cancer, identifying specific mutations is particularly critical. For instance, mutations in genes such as BRCA1 or BRCA2 ... Get a 320W portable power station and ...

A U.S. FDA panel of independent experts beat back an effort by Pfizer (NYSE:PFE) to expand the patient population for its prostate cancer treatment Talzenna (talazoparib). Members of the Oncologic ...

Former President Joe Biden’s diagnosis of an aggressive, stage-4 prostate cancer has reignited a long-simmering medical debate: When should men get screened for prostate cancer? For decades, doctors ...

ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Sharon Choi discussing comprehensive genomic profiling of Black and non-Hispanic White men with prostate cancer. Racial ...

Myriad Oncology provides a portfolio of advanced genetic and tumor genomic testing solutions, including risk assessment, ...

Myriad Genetics, Inc. (NASDAQ:MYGN) is making waves at the 2025 ASCO Annual Meeting, presenting seven new research studies ...

Plaintiffs in toxic tort cases must prove both general and specific causation, generally through the testimony of experts. Experts must establish ...

(UroToday.com) The 2025 ASCO annual meeting featured a prostate cancer session and a presentation by Dr. April Rose discussing a ctDNA–directed phase II study of carboplatin in patients with ...

The report, to be released Thursday, is expected to identify the key drivers of chronic childhood illness, such as asthma and ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...